Clinics I work with
Selected research
-
Neuro-Oncology Practice: Continuing to raise awareness of current practice and research opportunities in neuro-oncology.
Neuro-oncology practice
-
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Neuro-oncology
-
Intracranial mesenchymal tumor with FET-CREB fusion - a unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms.
Brain pathology (Zurich, Switzerland)
Clinical trials
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Crite...
Recruiting
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Adverse events will be monitored from just before investigational medicinal product (IMP) administration until the end of study participation. Vital signs (blood pressure and heart rate only) will be recorded at baseline and 30 mi...
Recruiting
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Patients will be monitored for the occurrence of AEs that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration and until 7 days after administration. Seriou...
Recruiting
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gli...
National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 will be used for scoring toxicity and adverse events. The severity and frequency of toxicity will be tabulated by the tested dose or doses using ...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2966